Centessa Pharmaceuticals Stock News

BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 20, 2021.

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,970,000 shares, an increase of 26.3% from the October 31st total of 1,560,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.50 and last traded at $11.56, with a volume of 386143 shares. The stock had previously closed at $11.60. Separately, Zacks Investment Research raised shares of Centessa Pharmaceuticals from a hold rating to a []

Centessa Pharmaceuticals (CNTA) has been struggling lately, but the selling pressure may be coming to an end soon.

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) insider Tia L. Bush acquired 5,000 shares of the companys stock in a transaction that occurred on Tuesday, November 16th. The shares were bought at an average cost of $12.46 per share, for a total transaction of $62,300.00. The transaction was disclosed in a document filed with the SEC, which is []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) Director Aaron Kantoff acquired 10,000 shares of the stock in a transaction dated Thursday, November 18th. The shares were bought at an average cost of $11.98 per share, for a total transaction of $119,800.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) CEO Saurabh Saha acquired 23,000 shares of the stock in a transaction dated Tuesday, November 16th. The stock was acquired at an average price of $12.28 per share, with a total value of $282,440.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) shares shot up 6.8% on Wednesday . The company traded as high as $13.39 and last traded at $13.39. 2,693 shares traded hands during trading, a decline of 99% from the average session volume of 198,217 shares. The stock had previously closed at $12.54. Separately, Zacks Investment Research raised shares of []

Centessa Pharmaceuticals (NASDAQ:CNTA) released its quarterly earnings data on Sunday. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.55) by $0.10, MarketWatch Earnings reports. Shares of NASDAQ CNTA traded down $0.21 during trading hours on Wednesday, reaching $12.33. 981 shares of the stock were exchanged, compared []

Centessa Pharmaceuticals (NASDAQ:CNTA) announced its quarterly earnings results on Sunday. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.55) by $0.10, MarketWatch Earnings reports. Shares of NASDAQ:CNTA traded up $0.62 on Tuesday, reaching $12.54. The company had a trading volume of 137,684 shares, compared to its []

~ Announced positive topline data from proof-of-concept study of SerpinPC in severe hemophilia A and B subjects not on prophylaxis, demonstrating 88% reduction in median Annualized Bleeding Rate ("

Citadel Advisors LLC purchased a new position in shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) in the second quarter, HoldingsChannel.com reports. The fund purchased 456,233 shares of the companys stock, valued at approximately $10,133,000. Several other institutional investors have also recently modified their holdings of CNTA. JPMorgan Chase & Co. acquired a new position in Centessa []

BOSTON and LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA) today announced that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at th

Centessa Pharmaceuticals plc (NASDAQ: CNTA) announced proof-of-mechanism data from the first three subjects in Phase 1 Part B study of ZF874 in Alpha-1 Antitrypsin Deficiency (AATD).  AATD is an a